Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C.
Q3 Highlights
- Raised $4.7M (after costs) in over-subscribed placement with funds to be used to complete Phase 1 study and accelerate technology pipeline developments
- Phase 1 study submitted for HREC review – approval received in early October
- Manufacturing and clinical site preparations remain on schedule for the commencement of the MagSenseTM HER2 breast cancer Phase 1 study in the fourth calendar quarter as planned
